Lazard Asset Management LLC cut its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 555,850 shares of the company's stock after selling 86,458 shares during the quarter. Lazard Asset Management LLC owned approximately 0.14% of Recursion Pharmaceuticals worth $3,757,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Decker Retirement Planning Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $26,000. Private Trust Co. NA acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $27,000. Farther Finance Advisors LLC lifted its position in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after acquiring an additional 1,353 shares during the period. NewEdge Advisors LLC lifted its position in Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after acquiring an additional 2,387 shares during the period. Finally, PNC Financial Services Group Inc. lifted its position in Recursion Pharmaceuticals by 220.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock worth $66,000 after acquiring an additional 6,758 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Price Performance
Shares of Recursion Pharmaceuticals stock traded up $0.06 during trading on Thursday, reaching $4.15. The company's stock had a trading volume of 7,440,317 shares, compared to its average volume of 13,281,049. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a market capitalization of $1.68 billion, a P/E ratio of -2.71 and a beta of 0.99. The business has a 50 day moving average price of $5.24 and a 200-day moving average price of $6.55.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. During the same quarter last year, the firm earned ($0.39) earnings per share. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Analysts Set New Price Targets
RXRX has been the subject of a number of recent research reports. Needham & Company LLC decreased their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Morgan Stanley decreased their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Finally, Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of "Hold" and an average target price of $7.60.
Read Our Latest Stock Report on RXRX
Recursion Pharmaceuticals Company Profile
(
Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
